Table 8 Serum lysozyme activity of treatment groups (µg/mL)

W1

92–115

(104 ± 7)^b

230-259.9

(244 ± 9)^a

189.75-203.55

(197 ± 4)^{b, A}

184-190.9

(187 ± 2)^{b, A}

179.4-193.2

(186 ± 4)^{b, A}

W2

88–110

(99 ± 6)^b

220-248.2

(234 ± 8)^a

181.15–194.7

(188 ± 40^{b, B}

176-182.6

(179 ± 2)^{b, B}

171.6-181.8

(178 ± 4)^{b, B}

W3

84–105

(95 ± 6)^b

210-237.3

(223 ± 8)^a

173.25-185.85

(180 ± 4)^{b, B}

168-174.3

(171 ± 2)^{b, B}

163.8-176.4

(170 ± 4)^{b, B}

W4

80–100

(90 ± 6)^b

200–226

(213 ± 8)^a

165–177

(171 ± 3)^{b, B}

160–166

(163 ± 2)^{b, B}

156–168

(162 ± 3)^{b, B}

P-value

0.007

< 0.001

0.009